2020 Volume 40 Issue 7 Pages 615-621
More than 50 years have passed since Fleckenstein named verapamil calcium-channel blocker based on efficacy as a coronary vasodilator for the first time in 1967. In the field of anesthesiology, calcium-channel blockers are used to suppress supraventricular arrhythmia, reduce coronary and cerebral vasospasm, and control hypertension. They may also be used for myocardial protection, relaxation of the uterus, and hypotensive anesthesia. Both volatile and intravenous anesthetics need attention to act mutually with calcium-channel blockers, due to inhibit heart and neuronal L type electric current. Recent challenges with respect to calcium-channel blockers include increasing use of various combination drugs and effects on cerebral circulation and cognitive function.
